Differential Impact of Immune Escape Mutations G145R and P120T on the Replication of Lamivudine-Resistant Hepatitis B Virus e Antigen-Positive and -Negative Strains

ABSTRACT Immune escape variants of the hepatitis B virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests. Recent data suggest a preferential selection of immune escape mutants in distinct peripheral blood leukocyte compartments of infected individuals. We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity. Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants. The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication. Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones. However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV. In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro. These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants, supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns.

[1]  J. Stockman,et al.  Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B , 2010 .

[2]  T. Luedde,et al.  Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. , 2009, Journal of hepatology.

[3]  F. Ginhoux,et al.  Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis , 2009, Hepatology.

[4]  S. Bhattacharya,et al.  Genetic Characterization of Hepatitis B Virus in Peripheral Blood Leukocytes: Evidence for Selection and Compartmentalization of Viral Variants with the Immune Escape G145R Mutation , 2009, Journal of Virology.

[5]  Ronald E. Rose,et al.  Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.

[6]  J. Dienstag.  Benefits and risks of nucleoside analog therapy for hepatitis B , 2009, Hepatology.

[7]  I. Gareen,et al.  National Institutes of Health consensus development conference statement: Management of hepatitis B , 2009, Hepatology.

[8]  T. Luedde,et al.  The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen–positive and hepatitis B e antigen–negative hepatitis B virus strains , 2009, Hepatology.

[9]  A. Craxì,et al.  Chronic hepatitis B: who to treat and which choice of treatment? , 2009, Expert review of anti-infective therapy.

[10]  V. Shah.  Therapy for portal hypertension: What is our pipeline? , 2009, Hepatology.

[11]  F. Zoulim,et al.  In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. , 2009, Gastroenterology.

[12]  Jörg Petersen,et al.  EASL Clinical Practice Guidelines: management of chronic hepatitis B. , 2009, Journal of hepatology.

[13]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[14]  F. Tacke,et al.  Symptomatic hepatitis B virus (HBV) reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. , 2008, The Journal of infectious diseases.

[15]  V. Soriano,et al.  Hepatitis B virus escape mutants induced by antiviral therapy. , 2008, The Journal of antimicrobial chemotherapy.

[16]  R. Tedder,et al.  Antiviral Resistance Mutations Potentiate hepatitis B virus Immune Evasion through Disruption of its Surface Antigen a Determinant , 2008, Antiviral therapy.

[17]  H. Thomas,et al.  Replicative competence of the T131I, K141E, and G145R surface variants of hepatitis B Virus. , 2007, The Journal of infectious diseases.

[18]  F. Akbar,et al.  Prevention of hepatitis B virus infection by vaccination: Progress and problems , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[19]  Z. Meng,et al.  The Amino Acid Residues at Positions 120 to 123 Are Crucial for the Antigenicity of Hepatitis B Surface Antigen , 2007, Journal of Clinical Microbiology.

[20]  E. Tabor.  Infections by hepatitis B surface antigen gene mutants in Europe and North America , 2006, Journal of medical virology.

[21]  M. Manns,et al.  CREB/PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter , 2005, Gut.

[22]  B. Weber.  Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. , 2005 .

[23]  M. Manns,et al.  Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance--implications for novel antiviral strategies. , 2004, Current medicinal chemistry.

[24]  C. Trautwein.  Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. , 2004, Journal of hepatology.

[25]  T. Luedde,et al.  Basal Core Promoter and Precore Mutations in the Hepatitis B Virus Genome Enhance Replication Efficacy of Lamivudine-Resistant Mutants , 2004, Journal of Virology.

[26]  H. Will,et al.  Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R , 2003, Hepatology.

[27]  M. Manns,et al.  Relevance of hepatitis B core gene deletions in patients after kidney transplantation. , 2003, Gastroenterology.

[28]  H. Isom,et al.  Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine‐resistant HBV in vitro , 2003, Hepatology.

[29]  C. Bolovan-Fritts,et al.  Mapping the viral genetic determinants of endothelial cell tropism in human cytomegalovirus. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[30]  J. Torresi.  The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[31]  M. Manns,et al.  Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. , 2002, Virology.

[32]  D. Jackson,et al.  Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. , 2002, Virology.

[33]  M. Manns,et al.  Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. , 2002, Gastroenterology.

[34]  M. Brunetto,et al.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. , 2002, Journal of hepatology.

[35]  A. Lok,et al.  World‐wide epidemiology of HBeAg‐negative chronic hepatitis B and associated precore and core promoter variants , 2002, Journal of viral hepatitis.

[36]  D. Vassilopoulos,et al.  Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.

[37]  G. Alexander,et al.  Hepatitis B virus surface mutations associated with infection after liver transplantation. , 1996, Journal of hepatology.